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Objectives: To evaluate the effects of 200 U/kg of sodium unfractionated heparin (UFH) on 
coagulation times in dogs after IV and SC administration and to compare these effects with 
plasma heparin concentrations assessed by its anti Xa activity. 
Methods: 200 U/kg of UFH were administered Intravenously (IV) and Subcutaneously (SC) to 
five healthy adult Beagle dogs with a wash out period of at least 3 days. Activated Partial 
Thromboplastin Time (APTT), Prothrombin Time (PT) and plasma anti-factor Xa (aXa) activity 
were determined in serial blood samples. 
Results: After IV injection, PT remained unchanged except for a slight increase in one dog; 
APTT was not measurable (> 60 s) for 45 to 90 min, then decreased regularly and returned to 
baseline values between 150 and 240 min. High plasma heparin concentrations were observed (C 
max = 4.64±1.4 aXa U/mL) and decreased according to a slightly concave-convex pattern on a 
semi-logarithmic curve but returned to baseline slightly more slowly (t240 to t300 min).  
After SC administration, APTT was moderately prolonged (mean±SD prolongation: 1.55±0.28 x 
APTT t0, range [1.35-2.01]) between 1 and 4 hours after administration. Plasma anti-factor Xa 
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activity reached a maximum of 0.56±0.20 aXa U/mL, range: [0.42 - 0.9] after 132±26.8 min and 
this lasted for 102±26.8 min.  
Heparin concentrations were grossly correlated to APTT; prolongation of APTT of 120 to 160% 
corresponded to plasma heparin concentrations range of 0.3-0.7 aXa U/mL, considered as the 
therapeutic range in human medicine.  
Conclusions: As in human, pharmacokinetic of UFH in dogs is non linear. Administration of 200 
U/kg of UFH SC in healthy dogs results in sustained plasma heparin concentrations in 
accordance with human recommendations for thrombosis treatment or prevention, without 
excessively increased bleeding risks. In these conditions, APTT can be used as a surrogate to 
assess plasma heparin concentrations. This has to be confirmed in diseased animals. 
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Introduction 
Heparin is a complex and heterogeneous glycosaminoglycan, widely used in human medicine to 
treat or to prevent thrombosis 1,2. Its main effect is the inhibition of two major enzymes of the 
coagulation cascade, activated factors X (fXa) and II (fIIa), through binding to a plasma protein, 
Antithrombin III (AT III) via a specific pentasaccharide sequence 1. Hypercoagulable states are 
far less common in veterinary practice than in human medicine. However, Disseminated 
Intravascular Coagulation (DIC), characterized by a hyperactivation of the hemostatic system, is 
recognized as a potential severe complication of various diseases in dogs, including neoplasia, 
septic shock or heat stroke 3-7. Treatment of DIC remains a challenge, even in humans, but 
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heparin, Antithrombin III, activated Protein C and Tissue Factor Pathway Inhibitor have been 
demonstrated to be of some benefit 8. Because of its low cost, heparin has also been 
recommended for dogs with DIC 3-5. Various therapeutic or prophylactic protocols are available 
in the veterinary literature: intravenous or subcutaneous administration, alone or with plasma 
transfusion, with doses ranging from 20 to 1000 U/kg 3-5. These dose regimens are mainly 
empirical or extrapolated from human clinical trials and rabbit models, and whether or not 
heparin would help dogs with suspected hypercoagulation states still remains uncertain 3,4,9. The 
potential benefits have to be balanced against the bleeding risk if overdosage occurs, especially 
in dogs with DIC which already have a bleeding tendency because of the increased consumption 
of coagulation factors. A better understanding of the pharmacology of heparin in dogs may help 
to prevent these therapeutic hazards, but until recently, the pharmacokinetic studies of heparin in 
dogs were mainly based on the interpretation of plasma coagulation times 10,11. Mischke et al in 
200112,13 studied the effect of various doses of UFH on different screening tests of hemostasis 
and their relationship with plasma aXa activity, but without pharmacodynamic analyses. Jacobs 
et al in 1999 14 studied the pharmacokinetics of heparin using the plasma anti-factor Xa activity 
to assess plasma heparin concentration, which has been shown to be more sensitive than plasma 
coagulation times in assessing pharmacodynamic parameters in men 15.  
However plasma anti-factor Xa activity determination is not a routine technique and plasma 
coagulation times (mainly Activated Partial Thromboplastin Time [APTT]) are used in human 
medicine to monitor the bleeding risk induced by heparin 16. In dogs, repeated SC 
administrations of 150 U/kg unfractionated Heparin were reported by Mischke et al in 2001 13 to 
only moderately increase coagulation times (APTT and Thrombin Time) whilst having 
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significant plasma anti-factor Xa activity, thus demonstrating that screening tests were not 
suitable for UFH monitoring.  
We studied the effect of the heparin dosage routinely used in the Ecole Nationale Vétérinaire de 
Toulouse (200 UI/kg of unfractionated heparin, SC) on plasma heparin concentration assessed 
by anti factor Xa activity and on plasma coagulation times in order to determine if this protocol 
should fulfilled the criteria of efficacy recommended in humans and could be monitored using 
APTT. We also studied the time-course effects of heparin administered subcutaneously and 
intravenously and its pharmacokinetic parameters. 
 
MATERIAL AND METHODS 
 
Dogs: Five healthy 3-5 year old adult Beagle dogs (4 males, 1 female), weighing 16 to 20 kg, 
were used in this study. No abnormalities were detected by physical, hematological or 
biochemical routine examinations. The dogs were allowed to drink, but food was withheld 12 
hours before the beginning of each experiment.  
 
Heparin: 200 U/kg of commercially available sodium unfractionated heparin (Héparine Choay, 
Sanofi Synthélabo, Gentilly, France) (5 000 U/mL) were administered:  
- 1) intravenously in a single bolus through a 22G catheter (Surflo, Terumo, Cestas, France) 
located in the radial vein; after injection, the catheter was flushed with 1 mL of NaCl 9‰ to 
ensure that all heparin had been administered. 
- 2) subcutaneously in the right thoracic wall of the dog.  
 
Study design: Both IV and SC studies were conducted on the dogs. The sequence of 
administration was randomly determined and a wash-out period of at least 3 days was allowed 
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between the two administrations. This was considered as a suitable length of times on the basis of 
pharmacokinetics of heparin in man and rabbits 15,17 and on previous studies on dogs 11,13,14. 
Blood samples (4.5 mL) were collected from the jugular vein into vacuum tubes containing 
sodium citrate (3.8%, 0.5 mL) (Venoject citrate, Terumo).  
For IV studies, a 0.7 mm microfuge (Venofix, Bruneau, Boulogne Billancourt, France) was 
placed in the right jugular vein to collect samples within the first 15 minutes following heparin 
administration to avoid repeated punctures. When blood was collected through this microfuge, 
the first milliliters of blood were discarded to avoid contamination by residual blood within the 
sampling device; after sampling, the microfuge was rinsed with 3 mL of NaCl 9‰.  
Blood samples were centrifuged within 30 minutes after collection (3000g, 10 min at 4°C) 
(Sigma 3K10, Bioblock, Illkirch, France); platelet-poor plasmas were stored at -20°C until being 
assayed within 2 months. 
Blood samples were obtained at times -20, 0, 1, 2, 3, 4, 5, 6, 8, 10, 15, 20, 30, 45, 60, 90, 120, 
150, 180, 240 and 300 min after IV administration and at times -15, 0, 30, 60, 90, 120, 150, 180, 
210, 240, 300, 360, 420, 480, 540, 600, 660 and 720 min after SC administration. 
 
Coagulation assays: APTT and Prothrombin Time (PT) were assessed using a steel ball semi-
automated device (ST4, Stago, Asnières, France) according to the manufacturer’s specifications. 
For APTT determination, 100 µL of plasma were incubated at 37°C for 3 min with 100 µL of 
cephalin and activator (CK Prest, Stago). 100 µL of 0.025 M CaCl2 were then added and the 
clotting time was recorded. For PT determination, 100 µL of plasma were added to 200 µL of 
tissue factor and calcium (Thromboplastine calcique, Biomérieux, Marcy L’Etoile, France) 
prewarmed to 37°C and the clotting time was recorded. The device automatically stopped if no 
clot appeared in 60 s. Reference intervals for APTT and PT were [10-13.5 s] and [6.5-8.5 s] 
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respectively. The intra and inter-assays variability were 2.9% and 2.2% respectively for APTT, 
and 2.1% and 1.8% for PT. 
 
Anti-factor Xa activity: Anti-factor Xa activity was determined in plasma samples by a kinetic 
chromogenic method using a commercial kit (Stachrom Heparin, Stago) adapted to the SBA 30 
Gilford automate (Ciba-Corning, Cergy-Pontoise, France) according to the specifications of the 
manufacturer, as described elsewhere 17. Briefly, 10 µL of plasma were added to 100 µL 
Antithrombin III (1 µM in Tris buffer, pH 7.4). After 3 s, 200 µL of factor Xa (5,6 nkat/mL in 
Tris Buffer) were added. 200 µL of factor Xa chromogenic substrate (CBS 31-39, 2.4 mM) were 
added after a 135 s incubation, and absorbance was recorded at 405 nm every 10 s. Calibration 
curves were obtained by heparin surcharge of autologous plasmas (r²=0.996). The reference 
interval was < 0.05 aXa U/mL.  
 
Data analysis: Results are expressed as mean ± SD. Time-course parameters of HNF were 
determined by non compartimental analysis of anti-factor Xa activities using a computer program 
(Win Non Lin 4.0, Pharsight Corporation, Montain View, CA, USA). The area under the plasma 
concentration-time curve (AUC) was derived using the linear trapezoidal curve extrapolated to 
infinity. C max were determined by visual inspection of the plasma concentration-time curves 
after the distribution phase. The apparent Mean Residence Time (MRT) was defined as AUMC 
(first moment of the plasma concentration-time profile) /AUC. The correlation between APTT 
and aXa activity was calculated using the Excel computer program (Microsoft France, Les Ulis, 
France). 
. 
 
RESULTS 
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Heparin side effects 
No adverse drug reaction, bleeding tendency or hematoma was observed after heparin 
subcutaneous administration. After intravenous administration, one dog demonstrated a slight 
bleeding in the jugular vein a few minutes after heparin administration, which was easily 
controlled by local compression. In the other dogs, small hematomas in the jugular area could be 
observed at the end of the experiments. 
 
Subcutaneous administration:  
Effects on plasma coagulation times  
A progressive increase of APTT started at t30 to t90 and APTT reached its maximum 90 to 150 
minutes after SC administration (Fig. 1A). This increase lasted 144±25.1 min [120 - 180 min] 
before returning to baseline values at 420±73.5 min [300 - 480 min] after heparin administration. 
The APTT was increased by a ratio of 1.55±0.28 compared to the APTT initial value (range: 
1.35-2.01).  
No significant PT variations were observed (Fig. 1B), except for dog 5 which had a PT slightly 
above usual values (8.9 s) from 240 to 360 min after heparin administration. 
 
Plasma heparin concentration  
The evolution of plasma heparin concentration, assessed by anti-factor Xa activity was roughly 
similar to the APTT (Fig. 1C). A significant increase began 48±16.4 min [30-60 min] after 
administration and the maximum (range: 0.42 to 0.9 aXa U/mL) occurred between 150 and 240 
min. The return to baseline values was observed between 420 to 480 min (mean±SD: 468±50.2 
min).  
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Intravenous administration:  
As complete IV administration of heparin was uncertain in dog 2, and the plasma concentration-
time curve differed significantly from the data obtained in the other dogs, results obtained with 
this dog were not included for IV study. 
 
 
Effects on plasma coagulation times  
APTT was not measurable (APTT > 60 s) until t45 min (dog 1) to t90 min (dogs 3 and 5). It then 
decreased regularly and returned to baseline at 218±45 min [range: 150-240 min]. 
PT was almost unchanged (Fig. 2B) except in dog 5, in which increased PT (up to 10.4s) were 
observed for 120 minutes after administration. 
 
 
Plasma heparin concentration  
Maximal heparin concentrations (t1: 6.08±2.07 aXa U/mL) were observed in all dogs 
immediately after the administration (figure 2C), followed by a distribution phase of 4 minutes. 
Plasma heparin then decreased regularly and returned to baseline values at 240 min (dog 4) or 
300 min (dogs 1 and 5). A moderate residual anti-factor Xa activity persisted at t300 in dog 3 
(0.08 aXa U/mL). When plotted on a semi-logarithmic scale, anti-factor Xa activity disappeared 
according to a slightly concave-convex two-phase pattern (Fig. 3). 
 
Correlation between APTT and plasma anti-factor Xa activity 
Only APTT shorter than 60 s were taken into account. Plasma heparin concentration assessed by 
anti-factor Xa activity was strongly correlated with APTT, when data collected from all dogs 
were pooled (r2 = 0.89, p<0.01) (Fig. 4) or when each dog was considered individually (r2 
ranging from 0.85 to 0.96, p<0.01). 
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Plasma heparin concentrations between 0.3 and 0.7 U/mL, i.e. considered in the therapeutic range 
in human medicine, corresponded approximately to a prolongation of APTT between 120 and 
165 % of APTT initial values. 
 
Pharmacokinetic parameters of heparin after IV and SC administration 
The results are summarized in table 1. The Area Under the Curve (AUC) of the anti-factor Xa 
Activity was 147.9±45.7 [109.7 - 224.3] and 350.8±123.7 [270.7 - 531.7] aXa U.min.mL-1 for SC 
and IV administrations respectively (mean ±SD). The apparent Mean Residence Time (aMRT) 
varied from 201.4 to 250.1 min for SC study (mean ±SD: 222.2±23.7 min) and from 58.8 to 65.7 
min (mean ±SD: 62.9±3.2 min) for IV study. Mean observed Cmax was 0.56±0.2 aXa U/mL after 
SC administration; Cmax of 4.64±1.4 aXa U/mL (mean±SD) was observed at t4min for IV study.  
Apparent bioavailability was 50±16%, ranging from 28% (dog 5) to 68% (dog 3). 
 
DISCUSSION 
This study was designed to investigate the effects of a therapeutic dose of unfractionated heparin 
on plasma anti-factor Xa activity, representing the plasma heparin concentration, and to 
determine its effects on the coagulation times routinely measured to monitor heparin therapy. 
 Different methods can be used to assess plasma heparin concentrations: plasma anti-factor 
Xa or anti-factor IIa activities, assessed by amydolytic assays, reflect the concentration of the 
heparin fraction containing the pentasaccharide sequence (high AT III affinity-heparin, HAH), 
whereas radiolabelled heparin explores the behavior of the entire compound. Some studies have 
compared data calculated from anti-factor Xa and anti-factor IIa in the rabbit after IV and SC 
administration of UH: they were almost identical 17. In contrast, some discrepancies between the 
results obtained by radiolabelled heparin and amydolytic assay have been observed in the 
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rabbit18; in our study in the dog, the decrease in plasma anti-factor Xa activity observed after IV 
administration was slower than was observed in dogs after a single IV injection of 1 mg/kg of 
[35S] UH (approximately 150 U/kg) 20 (as much as 66% of plasma radioactivity was lost within 
the first 15 min). This may be because HAH are cleared more slowly than the low affinity 
fraction (without the pentasaccharide) 19. Because HAH is the biologically active fraction, 
amydolytic assay is the most commonly used variable to assess heparin pharmacokinetics.  
 
 After IV administration, plasma heparin disappeared according to a slightly concave-
convex pattern on a semi-logarithmic plot in our study. Such concave-convex curves weren’t 
observed in the dog when lower UFH (25, 50 and 100 U/kg) doses were given in a previous study 
14, but similar nonlinear kinetics have been observed with high doses (>100 U/kg) of UH in 
rabbits 18,21 and humans 15 and analyzed as the combination of a highly efficient, saturable 
heparin uptake by the endothelial cells and a linear non saturable renal elimination 21-24. In the 
dog, renal elimination of radiolabelled UH was observed, whereas the high relative 
concentrations of [35S] UH found in the liver and spleen were consistent with heparin uptake by 
the reticuloendothelial system 20. Thus, it can be hypothesized that the elimination of UH in dogs 
is comparable to what is observed in man and rabbits. This may be of importance when treating a 
dog suffering from DIC, in which the renal function may be compromised 4.  
 Concerning pharmacokinetic parameters, our results were consistent with previous studies 
14,17. Distribution volume was close to the plasma volume (50 mL/kg) and comparable to data 
from other studies on the dog 14 and the rabbit 17. Due to the non linear kinetics, only apparent 
MRT can be calculated. After SC administration, aMRT in our study (222±23 min) was quite 
similar to the MRT reported after 250 UI/kg SC of UH by Jacobs 14 (3.7± 2.4 hours), but it was 
higher after IV administration of 200 U/kg than that was observed in the same study after IV 
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administration of 25, 50 or 100 U/kg UH in the dog 14. However, heparin aMRT has been 
demonstrated to be influenced by the dose administered: the higher the dose, the longer the 
apparent MRT 22.  
 
 As the APTT is influenced by heparin concentration in vivo and ex vivo, it has been used as 
a surrogate for plasma heparin concentrations. However, as has already been demonstrated in 
man 16,25, the APTT lacks sensitivity when plasma heparin concentrations are very low or very 
high. For example, in our study, the APTT after IV administration was longer than 60 s for at 
least 45 min in all dogs, whereas the plasma anti-factor Xa activity varied from 10 to 2,4 aXa 
U/mL. As 60 s is the upper limit of the automated coagulometer, we performed manual 
determinations of APTT in some plasma (data not shown): no clot was observed over 600 s and 
the blood was considered as uncoagulable. The lack of sensitivity of APTT may also be 
influenced by the reagent used, as observed with different reagents in man and in dogs 12,16,26. 
However in our experiments and in the range of plasma heparin concentrations obtained after SC 
administration, APTT-time curves were roughly similar to those of heparin-time and APTT 
strongly correlated with plasma anti-factor Xa activity.  
Much more convenient and far less expensive to assess than plasma anti-factor Xa, APTT is 
widely used in routine and it has also been correlated with the bleeding risk in men 2. A 1.5 to 2.5 
times prolongation in APTT 2, corresponding to plasma heparin concentrations ranging from 0.3 
to 0.6 U/mL 1 is the target of human therapy for thrombosis and has also been recommended in 
DIC-treated dogs 5,9. But, with our reagents, this prolongation was achieved by a heparin 
concentration two times higher. In this experiment, recommended heparin concentrations 
produced lower APTT values in dogs than in humans, as previously reported 12.  
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In contrast to APTT, PT is considered insensitive to heparin, as observed in healthy men or 
human patients receiving heparin for thrombosis therapy 15. Insensitivity of PT to heparin was 
also observed in most dogs in this study: even after IV administration, PT was only slightly 
prolonged for 20 minutes, whereas APTT remained not measurable for at least 45 min. 
Surprisingly, one dog (dog 5) demonstrated a weak PT prolongation after SC UH administration 
and a stronger one after IV administration when very high plasma heparin concentrations were 
achieved. This might be due to an individual variation of its hemostatic system, as after SC 
administration, PT in this dog was slightly increased whereas it was not in dog 3, which had the 
highest plasma anti-factor Xa activity. Despite this isolated observation in a single dog, it can be 
considered that a significant increase of PT in DIC dogs treated with heparin may be due to a 
worsening of DIC and consumption of coagulation factors rather than to heparin therapy itself. 
 
The dose of heparin used in this study was chosen through our experience in DIC therapy in dogs 
and data available in the literature 4,11. Concerning the efficiency and safety of heparin therapy 
protocols, SC administration of 200 UI/kg of UH induced a plasma heparin concentration in the 
therapeutic range between 1 to 6 hours after administration. IV bolus is not to be recommended 
due to the low aMRT and high peak concentrations, inducing a possible bleeding risk. A 
continuous infusion of UH would be interesting within a whole blood or plasma transfusion 
which also brings coagulation factors and ATIII. However, the UH infusion rate to maintain 
plasma heparin concentration in the [0.3-0.7 aXa U/mL] range is difficult to predict due to the 
non linear kinetic, and heparin continuous infusion protocols have been proved to increase the 
bleeding risks in men, compared to subcutaneous administration 2. 
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So, based on plasma heparin concentrations assessed by anti-factor Xa activity established in this 
study, administration of 200 U/kg of UFH SC results in plasma heparin concentrations 
considered as therapeutic in humans without excessively increasing bleeding risks. These 
concentrations corresponded to a 1.2 to 1.5 fold increase of APTT, which can be used as 
surrogate to plasma heparin concentration. The efficacy of such a dose regimen and the 
relationship between plasma heparin and APTT prolongation have yet to be confirmed in clinical 
trials with diseased animals. 
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Legends :  
Figure 1: Mean±SD Activated Partial Thromboplastine Time (APTT) (fig.1A), Prothrombin 
Time (PT) (fig.1B) and plasma heparin concentration assessed by anti Factor Xa activity (fig.1C) 
observed after subcutaneous administration of 200 U/kg of unfractionated heparin to healthy 
dogs. 
 
Figure 2: Mean±SD Activated Partial Thromboplastin Time (APTT) (fig.2A), Prothrombin Time 
(PT) (fig.2B) and plasma heparin concentration assessed by anti Factor Xa activity (fig.2C) 
observed after intravenous administration of 200 U/kg of unfractionated heparin to healthy dogs. 
 
Figure 3: Plasma heparin concentrations (mean±SD) assessed by anti-factor Xa activity (aXa 
U/mL) observed after intravenous administration of 200 U/kg of unfractionated heparin to 
healthy dogs  
 
Figure 4: Correlation between APTT (s) and plasma anti-factor Xa activity (U/mL) (s) after 
intravenous or subcutaneous administration of 200 U/kg of unfractionated heparin to healthy 
dogs. Plasma heparin (aXa U/mL) = 1.4165 Ln [APTT (s)]-3,485, r2=0.89. 
 
Table 1: Pharmacokinetic parameters established after IV and SC administrations of 200 U/kg of 
UH in healthy dogs. AUC = area under the curve, Cmax = maximal concentration, Vd = 
distribution volume, aMRT = apparent mean residence time, Cl = apparent clearance, aF = 
apparent bioavalability. 
 
 
 
 
 
 
 17
A10
15
20
25
-30 60 150 240 330 420 510 600 690
Tim e (m in)
A
P
TT
 (s
)
 
B
6
8
10
-30 60 150 240 330 420 510 600 690
Tim e (m in)
P
T 
(s
)
 
 
C
0
0,2
0,4
0,6
0,8
1
-30 60 150 240 330 420 510 600 690
T ime (min)
Pl
as
m
a 
he
pa
rin
 (a
Xa
U
/m
L)
 
Figure 1:  
 18
A0
2 0
4 0
6 0
-3 0 3 0 9 0 1 5 0 2 1 0 2 7 0
T im e (s )
A
P
TT
 (s
)
 
 
B
6
7
8
9
10
11
-30 30 90 150 210 270
T im e (s )
PT
 (s
)
 
 
C
0
2
4
6
8
10
-30 30 90 150 210 270
T im e (s )
Pl
as
m
a 
he
pa
rin
 (a
Xa
 
U
/m
L)
 
Figure 2:  
 19
A0,01
0,10
1,00
10,00
-30 20 70 120 170 220 270 320
Pl
as
m
a 
he
pa
rin
 (a
X
aU
/m
L)
T ime  (min)
 
Figure 3:  
 
0
0,5
1
1,5
2
2,5
3
0 10 20 30 40 50
APTT (s)
Pl
as
m
a 
he
pa
rin
 (U
aX
a/
m
L
60
)
 
Figure 4:  
 20
 
Pharmacokinetic parameters IV Results (m±SD) SC Results (m±SD) 
AUC (U.min.mL-1) 350.8±123.7 147.9±45.7 
Cmax (U. mL-1)  4.64±1.40 (t 4 min) 0.56±0.2 
Vd (mL.kg-1) 38.7±10.8  
aMRT (min) 62.9±3.2 222.2±23.7 
Cl (U.min-1.kg-1) 0.61±0.12 1.44±0.3 
aF (%)  50±16 
Table 1 
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Figure 3 (other possibility): Plasma heparin concentrations assessed by anti-factor Xa activity 
(aXa U/mL) observed after intravenous administration of 200 U/kg of unfractionated heparin to 4 
healthy dogs 
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